BofA lowered the firm’s price target on Bausch Health (BHC) to $5 from $7 and keeps an Underperform rating on the shares. The firm, in its preview of Q1 EPS updates for its commercial-stage biopharma coverage, notes that Q1 generally tends to be the “messiest” quarter for the group given seasonal factors and many companies tend to “get a pass” on the assumption growth and full year results will be second half weighted, adding that it thinks Q1 results “may take a ‘back seat’ to macro concerns around pharma tariffs.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- U.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case
- Bausch says court grants summary judgment in favor of FDA, Salix, and Teva
- Bausch Health Adopts Shareholder Rights Plan to Ensure Fair Treatment
- Bausch Health Canada signs Cabtreo public drug plan coverage letter of intent
- Bausch Health signs LOI with pan-Canadian Pharmaceutical Alliance for CABTREO
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue